clinical trial · NCT07301723
A Trial to Evaluate the Absolute Bioavailability of Cenerimod in Healthy Male Participants
Viatris Innovation GmbH·phase1·completed·n = 6
Healthy SubjectsCenerimod (oral)14C-Cenerimod (i.v.)
brief summary
The goal of this clinical trial is to learn about the absolute bioavailability of cenerimod in healthy participants. It will also provide information about the safety of cenerimod. Participants will receive one tablet with cenerimod, followed by an intravenous (i.v.) infusion with a 14C-radiolabeled cenerimod microtracer (cenerimod with a very low dose of radioactivity) 6 hours later. Participants will stay at the clinic for a total of 4 days, and will return to the clinic for further tests over the course of approximately 3 months.
started
Dec 11, 2025
primary completion
Mar 18, 2026
completion
Mar 18, 2026
last updated
Mar 30, 2026
official title
A Single-center, Open-label Trial to Determine the Absolute Bioavailability of Cenerimod Using an Intravenous 14C-radiolabeled Cenerimod Microtracer in Healthy Male Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol